Common Contracts
5 similar Letter Agreement contracts by Mirati Therapeutics, Inc.
ContractLetter Agreement • May 5th, 2020 • California
EX-10.25 7 mrtx-20161231xex1025.htm EXHIBIT 10.25 Exhibit 10.25 AMENDMENT TO LETTER AGREEMENT This Amendment to Letter Agreement (the “Amendment”) is entered into by Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), and Christopher LeMasters (“Employee”) and shall be effective as of December 19, 2016. The purpose of this Amendment is to provide Employee with certain severance benefits as described herein. The severance benefits set forth in this Amendment replace and supersede the severance benefits set forth in that certain Letter Agreement entered into as of September 13, 2016 (the “Employment Agreement”) as further described in Section 7 below. In consideration of the mutual covenants and promises contained herein, the continuing employment of Employee by the Company and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the Company and Employee, the Company and Employee agree as follows: Section 1. SEVERAN
AMENDMENT TO LETTER AGREEMENTLetter Agreement • March 9th, 2017 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment to Letter Agreement (the “Amendment”) is entered into by Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), and Christopher LeMasters (“Employee”) and shall be effective as of December 19, 2016.
AMENDMENT TO LETTER AGREEMENTLetter Agreement • March 9th, 2017 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment to Letter Agreement (the “Amendment”) is entered into by Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), and Jamie A. Donadio (“Employee”) and shall be effective as of December 19, 2016.
AMENDMENT TO LETTER AGREEMENTLetter Agreement • March 9th, 2017 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment to Letter Agreement (the “Amendment”) is entered into by Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), and Isan Chen, M.D. (“Employee”) and shall be effective as of December 19, 2016.
AMENDMENT TO LETTER AGREEMENTLetter Agreement • March 9th, 2017 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment to Letter Agreement (the “Amendment”) is entered into by Mirati Therapeutics, Inc., a Delaware corporation (the “Company”), and James Christensen, Ph.D. (“Employee”) and shall be effective as of December 19, 2016.
